Martingale Asset Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$349K Buy
5,979
+10
+0.2% +$590 0.01% 717
2026
Q2
$335K Sell
5,969
-3,950
-40% -$206K 0.01% 736
2026
Q1
$476K Buy
+9,919
New +$434K 0.01% 651
2025
Q4
– Sell
-13,919
Closed -$491K – 840
2025
Q3
$491K Sell
13,919
-20,804
-60% -$753K 0.01% 616
2025
Q2
$1.25M Buy
34,723
+20,709
+148% +$686K 0.03% 415
2025
Q1
$436K Buy
+14,014
New +$444K 0.01% 623
2024
Q3
– Sell
-11,818
Closed -$312K – 835
2024
Q2
$312K Buy
11,818
+1,013
+9% +$28.1K 0.01% 688
2024
Q1
$328K Buy
+10,805
New +$319K 0.01% 694

Other funds holding RPRX

Martingale Asset Management's RPRX Position: Q3 2026 in Review

Martingale Asset Management increased its Royalty Pharma (RPRX) stake by 0.17% in Q3 2026, buying an estimated $590 and bringing the position to 5,979 shares worth $349K. The position accounts for 0.01% of the portfolio, ranked #717.

Martingale Asset Management first reported a position in RPRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.25M in Q2 2025. 698 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Martingale Asset Management held 5,979 shares of Royalty Pharma worth $349K as of Q3 2026.
  • Martingale Asset Management bought 10 Royalty Pharma shares in Q3 2026, an estimated $590.
  • Royalty Pharma made up 0.01% of Martingale Asset Management's portfolio in Q3 2026, its #717 holding.
  • Martingale Asset Management first reported a position in Royalty Pharma in Q1 2024 and has held it in 8 quarters since.
  • Martingale Asset Management's Royalty Pharma position peaked at $1.25M in Q2 2025.
  • 698 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.